MUC1 Promotes Cancer Stemness and Predicts Poor Prognosis in Osteosarcoma.

Jian Liu,Yixi Xu,Tianqi Xu,Yixiong Liu,Jin Liu,Jia Chai,Yanru Yang,Peizhen Hu,Mingyang Li,Qingge Jia,Chen Zhang
DOI: https://doi.org/10.1016/j.prp.2023.154329
IF: 3.309
2023-01-01
Pathology - Research and Practice
Abstract:Osteosarcoma (OS) is one of the most common primary bone malignancy. Combining chemotherapy and surgical treatment significantly improved clinical outcomes for osteosarcoma patients. Osteosarcoma stem cells (OSCs) are often more malignant than differentiated cancer cells and are a key determinant of responses to chemotherapy and radiation therapy, therefore, the removal of OSCs could be an effective therapeutic strategy. Myxoprotein 1 (MUC1) is aberrantly overexpressed in many human cancers and it promotes cancer stemness through activation of pluripotency networks. In this study, we observed elevated MUC1 in osteosarcoma and a depressed prognosis in patients with high MUC1 expression profiles. Our observations also revealed that MUC1 promoted OS stemness and tumor metastasis both in vivo and in vitro. These data led us to hypothesize that MUC1 may be a therapeutic target for patients with OS.
What problem does this paper attempt to address?